Ginkgo bioworks stock prediction.

Ginkgo Bioworks Holdings stock price forecast: $1.25; Market Cap: 2.96B, Enterprise value: 1.61B, P/E: -1.01, PEG ratio: 0.20, EPS: -0.45, Revenue: 314.98M, ...

Ginkgo bioworks stock prediction. Things To Know About Ginkgo bioworks stock prediction.

The Ferment Co is a company creation studio for the next wave of synthetic biology product companies. The Ferment Co is powered by Ginkgo Bioworks, the world's most advanced platform for cell programming. Learn more at www.Ferment.co. Forward-Looking Statements of Ginkgo BioworksThe 7 analysts offering 12-month price forecasts for Ginkgo Bioworks Holdings Inc have a median target of 3.00, with a high estimate of 7.00 and a low estimate of 1.25.1 DNA stock price increased by 6.86% over the past day and the current price is below all major EMA’s. 2 Ginkgo Bioworks Holdings Inc. ( NYSE: DNA) stock’s 52-week price range is around $1.12 – $2.55. Ginkgo Bioworks Holdings Inc. reported Q2 revenue is down 44% Y-o-Y, mainly due to a fall in Biosecurity revenue.Analysts on Wall Street predict Ginkgo Bioworks will release losses per share of $0.091. Go here to follow Ginkgo Bioworks stock price in real-time ahead of earnings. On November 8,...RIJSWIJK, Netherlands and BOSTON, May 25, 2023 /PRNewswire/ -- Centrient Pharmaceuticals ("Centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and …

DNA Stock. USD 1.57 0.00 0.00%. Ginkgo Bioworks Holdings stock price prediction is an act of determining the future value of Ginkgo Bioworks shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Ginkgo Bioworks' future price could yield a ...By Tim McKinlay. • Published: April 26, 2023. • 1 Comment. It seems like everyone is talking about the power of AI these days, and Whitney Tilson has jumped on the bandwagon with a new AI-focused stock teaser pitch as well. In short, Tilson says that artificial intelligence (AI) is an “$87 trillion market,” and that it could “create ...

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership with Boehringer Ingelheim. The two companies will ...The current price Ginkgo Bioworks Holdings (DNA) is trading at is $1.43, which is within the analyst’s predicted range. Browse analyst ratings and price targets on all stocks. Popular Channels

Vivici Selects Ginkgo Bioworks to Extend Their Range of Novel Dairy Proteins ... into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock. ... These forward-looking statements are only predictions and involve known and unknown risks …Antonio Regalado. August 24, 2021. Mz Tech. The Boston genetic engineering company Ginkgo Bioworks and its CEO, Jason Kelly, have been spectacularly successful selling a story: that synthetic ...Ginkgo Bioworks ( DNA ): It is an innovative biotech enterprise. The renowned investor and founder of Ark Invest, Cathie Wood, has set her sights on three disruptive growth stocks that may soon ...Nov 22, 2023 · The Ginkgo Bioworks stock price fell by -3.50% on the last day (Wednesday, 22nd Nov 2023) from $1.43 to $1.38. During the last trading day the stock fluctuated 8.82% from a day low at $1.36 to a day high of $1.48. The price has risen in 5 of the last 10 days but is still down by -7.38% for this period. Volume has increased on the last day by ... Barron's 400. Research & Ratings. U.S.: NYSE. About Ginkgo Bioworks Holdings Inc. Research & Ratings. Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes ...

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. DNA | March 1, 2023. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance. 59 new Cell Programs added in 2022, representing 90% growth over 2021 and toward the high end of guidance.

Ginkgo BioWorks has an overall rating of 4.0 out of 5, based on over 118 reviews left anonymously by employees. 71% of employees would recommend working at Ginkgo BioWorks to a friend and 61% have a positive outlook for the business. This rating has decreased by -8% over the last 12 months.

Wall Street analysts forecast DNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 4.1 ...One of the best-performing stocks in today’s market is biotech company Ginkgo Bioworks (NYSE:DNA).Shares of DNA stock rocketed more than 20% higher in early afternoon trading.Contact Us U.S. markets close in 28 minutes S&P 500 +26.05(+0.57%) Dow 30 +272.05(+0.76%) Nasdaq +74.18(+0.52%) Russell 2000 1,852.18 +43.16(+2.39%) Crude Oil 74.32 -1.64(-2.16%) Gold 2,089.10...DNA Stock Forecast: Welcome to our series of Stock Forecasts, Predictions and Price Targets for 2023, 2024, 2025, 2030.Today we will analyse stocks from both technical and fundamental analysis and today’s stock is- DNA, DNA Stock Forecast 2023, 2024, 2025, 2030, 2040, 2050.This week was one to forget for Ginkgo Bioworks ( DNA 5.80%) shareholders. In the Monday-to-Friday period, their investment lost slightly more than 8% of its value on the stock market, according ...BOSTON, Sept. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced the launch of Ayana Bio to enable a healthier future by harnessing bioactive compounds for use as complementary medicine to support human health and wellness. Ginkgo, which recently …Jul 19, 2023 · How This Affects DNA Stock. Ginkgo Bioworks securing an $18 million contract over a four-year period is exciting investors. It shows the company’s research is valued by a government agency ...

In the past year, Ginkgo's growth rate has been falling. And for the last three months of 2022, its revenue fell by 34% year over year as a result of what management said was an "expected ...Price Target. Based on short-term price targets offered by eight analysts, the average price target for Ginkgo Bioworks Holdings, Inc. comes to $3.46. The forecasts range from a low of $1.25 to a ...There’s reason for this optimism around DNA stock. Ginkgo Bioworks is a company focused on using synthetic biology to reprogram cells.Presentation and Q&A session scheduled for post-market on Wednesday, March 1, 2023. BOSTON, Feb. 22, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for …Mar 29, 2022 · What happened. Shares of Ginkgo Bioworks ( DNA 5.80%) were jumping 18.2% higher as of 10:58 a.m. ET. The nice gain came after the company announced its 2021 fourth-quarter and full-year results ... About Ginkgo Bioworks. Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse ...Ginkgo further revised its expectation for Total revenue from $375 – $390 million to $425 –$440 million in 2022. Ginkgo continues to expect Foundry revenue of $165 – $180 million in 2022 ...

BOSTON, Sept. 9, 2021 /PRNewswire/ -- Ginkgo Bioworks ("Ginkgo"), which is building the leading horizontal platform for cell programming, today announced the launch of Ayana Bio to enable a ...

49.41M. AMZN. 145.18. +1.65%. 47.06M. View today's Ginkgo Bioworks Holdings stock price and latest DNA news and analysis. Create real-time notifications to follow any changes in the live stock price.Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and ...Ginkgo Bioworks currently has 1 sell rating, 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DNA, but not buy more shares or sell existing shares.Ginkgo Bioworks (NYSE:DNA) Is among the more prominent stocks in the synthetic biology space. The company is located in Boston, Massachusetts, which is a …Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results. $314 million of Total revenue in 2021, representing an increase of 309% over 2020. 31 new Cell Programs added in 2021 ...Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares rose 17.5% to $4.10 in pre-market trading after the company said Q2 sales results were up year ... Also check this out: Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday . Indic...Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share. Ginkgo Bioworks has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More.Ginkgo Bioworks Holdings; Stock Predictons by days: 2024 Ginkgo Bioworks Holdings Stock Forecast ... Stock, Forex Predictions, Forecasts & Charts – WalletInvestor.com Forecast GET PREMIUM . Crypto Forecast Stock Forecast ...Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31 ...

This week was one to forget for Ginkgo Bioworks ( DNA 5.80%) shareholders. In the Monday-to-Friday period, their investment lost slightly more than 8% of its value on the stock market, according ...

Ginkgo's platform remains a (promising) work in progress. Ginkgo Bioworks isn't like most biotechs. Rather than developing medicines or technologies to license out, its main segment is its biofoundry.

Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. [Read more] In 2022, DNA's revenue was $477.71 million, an increase of 52.21% compared to the previous year's $313.84 million. Losses were -$2.10 billion, 15.0% more than in 2021.Ginkgo Bioworks (NYSE: DNA) sells something very original: the large-scale design and production of organisms. And thanks to its innovations, the company has increased revenue almost 800% over the ...The average analyst rating for DNA stock from 4 stock analysts is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market …Ginkgo Bioworks Holdings Stock (NYSE:DNA), Analyst Ratings, Price Targets, Predictions. Analysts publish ratings and price targets on most stocks. Benzinga ...We can see that Ginkgo Bioworks Holdings does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors.By William White, InvestorPlace Writer Jul 19, 2023. Ginkgo Bioworks (DNA) stock is rising higher on Wednesday after the company won a four-year, $18 million contract from DARPA.By William White, InvestorPlace Writer Jul 19, 2023. Ginkgo Bioworks (DNA) stock is rising higher on Wednesday after the company won a four-year, $18 million contract from DARPA.Ginkgo Bioworks Holdings' estimated fair value is US$1.81 based on 2 Stage Free Cash Flow to Equity. Current share price of US$1.33 suggests Ginkgo Bioworks Holdings is potentially 26% undervalued ...BOSTON, Jan. 11, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today preliminary performance updates for ...Cambrium, a leading German start-up focused on the application of generative AI to protein design and synthesis, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform ...About Ginkgo Bioworks Holdings Inc. Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food ...

Which Ginkgo Bioworks insiders have been buying company stock? The following insider purchased DNA shares in the last 24 months: Shyam Sankar ($512,000.00). How much insider buying is happening at Ginkgo Bioworks?Added 21 new Cell Programs to the Foundry platform in Q2 2023, representing 62% growth over the prior year period. Ginkgo's Cell Engineering segment generated services revenue, which does not ...Based on Ginkgo Bioworks Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $80.7 million and a GAAP net loss of $204.97 million.Instagram:https://instagram. best stock brokers for day tradingtop moving stocks todayhealthcare mortgage programbest insurance for manufactured homes Ginkgo Bioworks. Ginkgo Bioworks investors can't seem to catch a break. The stock is trading lower in 2023's otherwise buoyant market, which follows a 63% drop last year.The latest step down came ...Sep 17, 2021 · Ginkgo Bioworks, a synthetic biology company now valued at around $15 billion, begins trading on the New York Stock Exchange today. Ginkgo’s market debut is one of the largest in biotech history. sp mini futuresstock psec The combined company is named Ginkgo Bioworks Holdings, Inc., and the combined company's shares of Class A common stock and public warrants will begin trading today on the New York Stock Exchange ...While Ginkgo Bioworks is an exciting company, the pricing of the SPAC stock leaves a lot of room for things to go wrong between now and the company's long-term projections. taj group of hotels in india Which executives are buying and selling shares of Ginkgo Bioworks stock? View the latest DNA insider trading activity at MarketBeat. Skip to main content. S&P 500 4,594.63. DOW 36,245.50. QQQ 389.94. 15 best consumer discretionary stocks for the rest of …As of June 2, 2023, the average one-year price target for Ginkgo Bioworks Holdings Inc - is 4.55. The forecasts range from a low of 1.77 to a high of $12.60. The average price target represents an ...Jason R. Kelly, who serves as the Director, CEO, and Founder of Ginkgo Bioworks Holdings, sold a total of 200,000 shares for $360,400. After this transaction, …